Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Actelion Pharmaceuticals U.S., Inc.
WARNING LETTER
•Actelion Pharmaceuticals U.S., Inc.•July 20, 2009

Actelion Pharmaceuticals U.S., Inc. – FDA Warning Letter, Jul 20, 2009

Record Details

On September 14, 2010, the FDA issued a Warning Letter to Actelion Pharmaceuticals U.S., Inc. following an inspection from June 24 to July 20, 2009. The inspection focused on Actelion's compliance with Postmarketing Adverse Drug Experience (PADE) reporting requirements for Tracleer® (bosentan), Ventavis® (iloprost), and Zavesca® (miglustat).

The FDA found that Actelion failed to comply with postmarketing reporting requirements under 21 U.S.C. § 355(k) [Section 505(k) of the Federal Food, Drug, and Cosmetic Act (the Act)] and 21 C.F.R. Section 314.80, constituting a prohibited act under Section 301(e) of the Act [21 U.S.C. § 331(e)].

Key violations included: 1. **Failure to develop adequate written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences (21 C.F.R § 314.80):** Actelion's procedures for Tracleer® and Ventavis® patient-support programs did not require expedited reporting of deaths within 15 calendar days when there was a "reasonable possibility" the drug caused

Company
Actelion Pharmaceuticals U.S., Inc.
Inspection date
July 20, 2009
Product type
Drugs
Office
Department of Health and Human Services
People
  • Barbara J. Cassens (Director )
  • Shalom Jacobovitz
View Company Profile

ID · d2054a2e-15b2-4c2b-b69f-9cf7cbd65220

Violation Codes8
21 U.S.C. 355(k)21 U.S.C. 331(e)21 CFR 314.8021 CFR 314.80(b)21 CFR 314.80(e)(1)21 CFR 314.80(c)21 CFR 314.80(e)21 CFR 314.90

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Actelion Pharmaceuticals U.S., Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.